Axsome Therapeutics Inc
NASDAQ:AXSM
Axsome Therapeutics Inc
PP&E Net
Axsome Therapeutics Inc
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Axsome Therapeutics Inc
NASDAQ:AXSM
|
PP&E Net
$6m
|
CAGR 3-Years
88%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
PP&E Net
$20.9B
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
PP&E Net
$8.4B
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
|
Pfizer Inc
NYSE:PFE
|
PP&E Net
$18.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
5%
|
CAGR 10-Years
5%
|
|
|
Merck & Co Inc
NYSE:MRK
|
PP&E Net
$23.8B
|
CAGR 3-Years
6%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
PP&E Net
$17.1B
|
CAGR 3-Years
24%
|
CAGR 5-Years
15%
|
CAGR 10-Years
8%
|
|
Axsome Therapeutics Inc
Glance View
Axsome Therapeutics Inc. emerged as a dynamic player in the biopharmaceutical arena, driven by a resolute commitment to alleviate the burdensome effects of central nervous system (CNS) disorders. Founded with a vision to fill critical treatment gaps in neurologically influenced conditions, Axsome leverages innovative drug discovery and development to address medical needs that have long been underserved. The company focuses intently on conditions such as depression, migraine, narcolepsy, and Alzheimer's disease-related agitation, channeling resources into a streamlined pipeline that seeks to fast-track the development and commercialization of life-changing therapies. Operating at the intersection of cutting-edge science and patient-centric healthcare, Axsome generates revenue through the successful approval and marketing of its proprietary pharmaceutical products. The company's business model hinges on advancing its clinical candidates through rigorous trials, eventually gaining the necessary regulatory endorsements to bring them to market. By holding the intellectual property rights for these novel drugs, Axsome enjoys the advantages of exclusivity in the marketplace, which allows it to negotiate favorable pricing and reimbursement terms. This strategic approach not only positions Axsome as a potentially transformative force within the pharmaceutical industry but also underlines its commitment to producing viable, accessible treatments for those grappling with debilitating CNS disorders.
See Also
What is Axsome Therapeutics Inc's PP&E Net?
PP&E Net
6m
USD
Based on the financial report for Dec 31, 2024, Axsome Therapeutics Inc's PP&E Net amounts to 6m USD.
What is Axsome Therapeutics Inc's PP&E Net growth rate?
PP&E Net CAGR 3Y
88%
Over the last year, the PP&E Net growth was -22%. The average annual PP&E Net growth rates for Axsome Therapeutics Inc have been 88% over the past three years .
You don't have any saved screeners yet